Holen Sie sich die Stockscreener-App
2.73
4.55%
-0.13
Handel nachbörslich:
2.71
-0.02
-0.73%
Schlusskurs vom Vortag:
$2.86
Offen:
$2.8
24-Stunden-Volumen:
174.45K
Relative Volume:
0.12
Marktkapitalisierung:
$23.89M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-3.3846
EPS:
-0.8066
Netto-Cashflow:
-
1W Leistung:
-9.90%
1M Leistung:
+22.97%
6M Leistung:
-8.17%
1J Leistung:
-20.87%
1-Tages-Spanne:
$2.71
$2.86
1-Wochen-Bereich:
$2.52
$3.30
52-Wochen-Spanne:
$1.33
$6.20
Neuraxis Inc Stock (NRXS) Company Profile
Firmenname
Neuraxis Inc
Sektor
Branche
Telefon
(812) 689-0791
Adresse
11550 North Meridian Street, Suite 325, Carmel
Vergleichen Sie NRXS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NRXS
Neuraxis Inc
|
2.73 | 28.87M | 0 | 0 | 0 | 0.00 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Neuraxis Inc Aktie (NRXS) Neueste Nachrichten
NeurAxis, Inc. Releases Investor Presentation - TipRanks
NeurAxis to Participate in the Lytham Partners Spring 2025 Investor Conference on May 29, 2025 - The Manila Times
Biotech Alert: Searches spiking for these stocks today - TipRanks
NeurAxis Closes $5 Million Direct Offering - marketscreener.com
NeurAxis, Inc. Completes $5 Million Registered Direct Offering to Support Growth of IB-Stim Therapy - Nasdaq
NeurAxis Announces Closing of $5.0 Million Registered Direct Offering - GlobeNewswire
NeurAxis announces USD 5M registered direct offering - Medical Buyer
NeurAxis, Inc. Announces $5 Million Stock Offering - TipRanks
Form 424B5 Neuraxis, INC - StreetInsider
SEC Form 424B5 filed by Neuraxis Inc. - Quantisnow
NeurAxis slides 21%, raises $5M via stock - MSN
Neuraxis settles lawsuit with $750,000 agreement By Investing.com - Investing.com South Africa
NeurAxis, Inc. Receives $1 Million from Warrant Exercises - TipRanks
Neuraxis settles lawsuit with $750,000 agreement - Investing.com
NeurAxis To Sell About 1.5 Mln Stock At $3.25/shr; Stock Plunges In Pre-market - Nasdaq
NeurAxis (NRXS) Announces $5M Direct Stock Offering - GuruFocus
NeurAxis Launches $5 Million Direct Offering - marketscreener.com
NeurAxis (NRXS) Announces Direct Stock Offering to Raise $5 Mill - GuruFocus
Neuraxis prices 1.54M shares at $3.25 in registered direct offering - TipRanks
NeurAxis Announces $5.0 Million Registered Direct Offering - The Manila Times
Edible Garden's Sports Nutrition Launch On Amazon Sends Stocks Climbing - Finimize
NeurAxis Awarded First Ever FDA Clearance for the Treatment - GlobeNewswire
NeurAxis Stock Soars on Groundbreaking FDA Clearance for Pediatric Treatment - Wall Street Pit
Gold Gains Over 1%; Amer Sports Posts Upbeat Earnings - Benzinga
Wall Street’s Dramatic Shifts Uncover Unexpected Winners and Losers—What’s Behind Today’s Wild Market Moves? - macholevante.com
NeurAxis Shares Climb After FDA Clearance of IB-Stim for Treating Pediatric Dyspepsia - marketscreener.com
NeurAxis (NRXS) Stock Surges Following Breakthrough FDA Clearance - Stocks Telegraph
Neuraxis, Inc. Common Stock (NYSE:NRXS) Stock Quote - FinancialContent
Nasdaq Falls 100 Points; Home Depot Sales Top Views - Benzinga
NRXS stock touches 52-week high of $5.67 amid market fluctuations - Investing.com
Pre-market Movers: NRXS, EYEN, TIL, HCTI, EKSO... - RTTNews
NeurAxis (NRXS) Gains FDA Clearance for Expanded Use of IB-Stim - GuruFocus
Neuraxis Awarded First Ever FDA Clearance For The Treatment Of Pediatric FAP/Functional Dyspepsia (FD) and Associated Nausea Symptoms - marketscreener.com
Neuraxis awarded FDA clearance for treatment of pediatric FAP, FD symptoms - TipRanks
NeurAxis Awarded First Ever FDA Clearance for the Treatment of Pediatric FAP/Functional Dyspepsia (FD) and Associated Nausea Symptoms - Yahoo Finance
NeurAxis Stock Gains Following Strong Q1 Earnings and FDA Milestones - MSN
NeurAxis Stock Gains Following Strong Q1 Earnings And FDA Milestones - Barchart.com
NeurAxis (NRXS) Sees Q1 Revenue Surge; Eyes Future Growth Opport - GuruFocus
NeurAxis, Inc. Reports Increased Sales Amidst Losses - TipRanks
NeurAxis Earnings Call: Growth Amid Challenges - TipRanks
Transcript : NeurAxis, Inc., Q1 2025 Earnings Call, May 12, 2025 - marketscreener.com
Earnings call transcript: Neuraxis sees 39% revenue boost in Q1 2025 - Investing.com Nigeria
NeurAxis, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Neuraxis reports Q1 EPS (33c) vs. (32c) last year - TipRanks
NeurAxis, Inc. Reports 39% Revenue Growth in Q1 2025 Amid Expansion of Neuromodulation Therapies - Nasdaq
NeurAxis Reports Strong First Quarter 2025 Financial Results Driven by a 39% Growth in Revenues - GlobeNewswire
Vagus Nerve Stimulators Market Is Booming Worldwide | LivaNova - openPR.com
Crude Oil : How we spotted the direction based on Elliott Wave - The Globe and Mail
NeurAxis to Host First Quarter 2025 Results and Business Update Call on Monday, May 12, 2025 - The Manila Times
350 Million Reasons to Buy Meta Platforms Stock After Q1 Earnings - The Globe and Mail
The Zacks Analyst Blog Highlights Amazon, Johnson & Johnson, Cisco Systems and NeurAxis - Yahoo Finance
Finanzdaten der Neuraxis Inc-Aktie (NRXS)
Es liegen keine Finanzdaten für Neuraxis Inc (NRXS) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
1.89%
3.74%
Kapitalisierung:
|
Volumen (24h):